항체 특이성 검사 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Antibody Specificity Testing Market Summary

The global antibody specificity testing market size was estimated at USD 938.6 million in 2024 and is anticipated to reach USD 1,776.1million by 2033, growing at a CAGR of 7.56% from 2025 to 2033. The rising need for high-quality antibodies in life science research, diagnostics, and therapeutic applications fuels the expansion of this market.

Increasing concerns over reproducibility in biomedical studies and stringent regulatory requirements for validated antibodies are accelerating the adoption of advanced specificity testing methods. Moreover, continuous advancements in proteomics, the growing focus on personalized medicine, and the surge in antibody-based drug discovery are expected to create substantial growth opportunities during the forecast period.

Global Antibody Specificity Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global antibody specificity testing market report on the basis of product & services, technology, application, end use, and region:

• Product & Services Outlook (Revenue, USD Million, 2021 - 2033)
• Products
  • Antibodies
  • Control & Standards
  • Kits & Reagents
  • Gene Validation Tools
• Antibody Validation & Specificity Testing Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassay-based Technologies
  • Western Blotting
  • Immunochemistry
  • Flow Cytometry
  • Others
• Genetic Validation-based Technologies
• Microarray-based Antibody Technologies
• Other Technologies
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Research & Development
  • Drug Discovery & Development
  • Proteomics & Biomarker Discovery
• Clinical Diagnostics
  • Infectious Diseases
  • Oncology
  • Immunology & Autoimmune Disorders
  • Neurodegenerative Disorders
  • Metabolic Disorders
  • Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Diagnostic Laboratories
• Other End Use
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
  • 1.4.3. Objective 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing use of antibody-based therapeutics
    • 3.2.1.2. Advancements in proteomics & genomics
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of standardized validation protocols
    • 3.2.2.2. High cost of advanced validation technologies
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Product & Services Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Antibody Specificity Testing Market Product & Services Movement Analysis
• 4.3. Global Antibody Specificity Testing Market Size & Trend Analysis, by Product & Services, 2021 to 2033 (USD Million)
• 4.4. Products
  • 4.4.1. Products Market, 2021 - 2033 (USD Million)
    • 4.4.1.1. Antibodies
      • 4.4.1.1.1. Antibodies Market, 2021 - 2033 (USD Million)
    • 4.4.1.2. Control & Standards
      • 4.4.1.2.1. Control & Standards Market, 2021 - 2033 (USD Million)
    • 4.4.1.3. Kits & Reagents
      • 4.4.1.3.1. Kits & Reagents Market, 2021 - 2033 (USD Million)
    • 4.4.1.4. Gene Validation Tools
      • 4.4.1.4.1. Gene Validation Tools Market, 2021 - 2033 (USD Million)
• 4.5. Antibody Validation & Specificity Testing Services
  • 4.5.1. Antibody Validation & Specificity Testing Services Market, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Antibody Specificity Testing Market Technology Movement Analysis
• 5.3. Global Antibody Specificity Testing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.4. Immunoassay-based Technologies
  • 5.4.1. Immunoassay-based Technologies Market, 2021 - 2033 (USD Million)
  • 5.4.2. Western Blotting
    • 5.4.2.1. Western Blotting Market, 2021 - 2033 (USD Million)
  • 5.4.3. Immunochemistry
    • 5.4.3.1. Immunochemistry Market, 2021 - 2033 (USD Million)
  • 5.4.4. Flow Cytometry
    • 5.4.4.1. Flow Cytometry Market, 2021 - 2033 (USD Million)
  • 5.4.5. Others
    • 5.4.5.1. Others Market, 2021 - 2033 (USD Million)
• 5.5. Genetic Validation-based Technologies
  • 5.5.1. Genetic Validation-based Technologies Market, 2021 - 2033 (USD Million)
• 5.6. Microarray-based Antibody Technologies
  • 5.6.1. Microarray-based Antibody Technologies Market, 2021 - 2033 (USD Million)
• 5.7. Other Technologies
  • 5.7.1. Other Technologies Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Antibody Specificity Testing Market Application Movement Analysis
• 6.3. Global Antibody Specificity Testing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Research & Development
  • 6.4.1. Research & Development Market, 2021 - 2033 (USD Million)
  • 6.4.2. Drug Discovery & Development
    • 6.4.2.1. Drug Discovery & Development Market, 2021 - 2033 (USD Million)
  • 6.4.3. Proteomics & Biomarker Discovery
    • 6.4.3.1. Proteomics & Biomarker Discovery Market, 2021 - 2033 (USD Million)
• 6.5. Clinical Diagnostics
  • 6.5.1. Clinical Diagnostics Market, 2021 - 2033 (USD Million)
  • 6.5.2. Infectious Diseases
    • 6.5.2.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 6.5.3. Oncology
    • 6.5.3.1. Oncology Market, 2021 - 2033 (USD Million)
  • 6.5.4. Immunology & Autoimmune Disorders
    • 6.5.4.1. Immunology & Autoimmune Disorders Market, 2021 - 2033 (USD Million)
  • 6.5.5. Neurodegenerative Disorders
    • 6.5.5.1. Neurodegenerative Disorders Market, 2021 - 2033 (USD Million)
  • 6.5.6. Metabolic Disorders
    • 6.5.6.1. Metabolic Disorders Market, 2021 - 2033 (USD Million)
  • 6.5.7. Others
    • 6.5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. Antibody Specificity Testing Market: End Use Movement Analysis
• 7.2. Pharmaceutical and Biotechnology Companies
  • 7.2.1. Pharmaceutical and Biotechnology Companies Market, 2021 - 2033 (USD Million)
• 7.3. Academic and Research Institutions
  • 7.3.1. Academic and Research Institutions Market, 2021 - 2033 (USD Million)
• 7.4. Diagnostic Laboratories
  • 7.4.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
• 7.5. Other End Use
  • 7.5.1. Other End Use Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Antibody Specificity Testing Market Share By Region, 2024 & 2033
• 8.2. North America
  • 8.2.1. North America Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Regulatory framework
    • 8.2.2.3. Competitive Scenario
    • 8.2.2.4. U.S. Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Regulatory framework
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Canada Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Regulatory framework
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Mexico Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Regulatory framework
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. UK Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Regulatory framework
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Germany Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Regulatory framework
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. France Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Regulatory framework
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Italy Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Regulatory framework
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Spain Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Regulatory framework
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Denmark Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Regulatory framework
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Sweden Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Regulatory framework
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Norway Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Japan Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. China Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. India Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Regulatory framework
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Australia Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Regulatory framework
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Thailand Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Regulatory framework
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. South Korea Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Brazil Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Argentina Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. South Africa Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Saudi Arabia Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. UAE Antibody Specificity Testing Market, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Kuwait Antibody Specificity Testing Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Danaher
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Bio-Rad Laboratories, Inc.
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Merck KGaA
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Cell Signaling Technology, Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. BD
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Novus Biologicals
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. OriGene Technologies, Inc.
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Creative Diagnostics
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. GenScript
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives